What does nosebleed from nasopharyngeal carcinoma look like

What does nosebleed from nasopharyngeal cancer look like?

1. The main early symptoms of nasopharyngeal carcinoma are nosebleeds or suctioning of bloody sputum from the nose, which often occur after getting up in the morning and are often ignored by patients. Symptoms include unilateral nosebleeds, blowing nosebleeds, unilateral nosebleeds, unilateral tinnitus, unilateral hearing loss, etc.

2. Bleeding is a common early symptom of nasopharyngeal carcinoma, mainly manifested as nosebleeds or blood in nasal sputum, which often occurs after getting up in the morning, but the amount of blood is not much and is often ignored by patients.

Recurrence rate of nasopharyngeal carcinoma after five years of treatment in the middle and late stages

Nasopharyngeal carcinoma is a common malignant tumor. Most early-stage nasopharyngeal carcinomas can be cured by radiotherapy. The recurrence rate of mid- and late-stage nasopharyngeal carcinoma is 100%. Cancer is still an incurable disease. Comprehensive treatment is used to control the disease, alleviate symptoms, and prolong life.

Some patients will have recurrence or metastasis after treatment, which is more common after treatment1-2 The recurrence rate may be as high as 80%. The clinical recurrence rate of nasopharyngeal carcinoma is very high.

What are the targeted drugs for nasopharyngeal carcinoma?

For nasopharyngeal carcinoma with lung metastasis, the overall prognosis of the late clinical stage is poor, and the main treatment is a combination of radiotherapy and chemotherapy. Regular follow-up examinations are required after radiotherapy and chemotherapy to understand the changes in tumor size.

Targeted drugs for nasopharyngeal carcinoma include EGFR monoclonal antibodies, which are often used in patients with epidermal growth factor receptor-positive nasopharyngeal carcinoma in the middle and late stages. They can be combined with chemotherapy to treat targeted drugs and improve the efficacy. Targeted drugs for nasopharyngeal carcinoma mainly include monoclonal antibodies and tyrosine kinase inhibitors.